In inflammatory bowel disease models including ulcerative colitis and cysteamine-induced colitis, BPC-157 reduces inflammatory markers (IL-6, TNF-, IL-1), improves mucosal architecture, and accelerates healing of damaged intestinal tissue
Additionally, certain medications including anticonvulsants and nucleoside analogues used in the treatment of HIV infection, may produce a secondary L-carnitine deficiency
DeAngelis AM, Roy-OReilly M, Rodriguez A
Our skilled team is here to guide and support your weight loss journey with comprehensive care
Ferre, G
[DOI] [PubMed] [Google Scholar] 161.Nigro E., Matteis M., Roviezzo F., Mattera Iacono V., Scudiero O., Spaziano G., Tartaglione G., Urbanek K., Filosa R., Daniele A., et al